Cartesian Therapeutics, Inc.
RNAC · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $452 | $298 | $1,100 | -$759 |
| % Growth | 51.7% | -72.9% | 244.9% | – |
| Cost of Goods Sold | $12,797 | $0 | $0 | $0 |
| Gross Profit | -$12,345 | $298 | $1,100 | -$759 |
| % Margin | -2,731.2% | 100% | 100% | 100% |
| R&D Expenses | $13,802 | $14,869 | $14,674 | $11,306 |
| G&A Expenses | $6,590 | $7,240 | $8,315 | $7,087 |
| SG&A Expenses | $7,716 | $7,240 | $8,315 | $7,087 |
| Sales & Mktg Exp. | $1,126 | $0 | $0 | $0 |
| Other Operating Expenses | -$12,797 | $0 | $0 | $7,579 |
| Operating Expenses | $8,721 | $22,109 | $22,989 | $25,972 |
| Operating Income | -$21,066 | -$21,811 | -$21,889 | -$26,731 |
| % Margin | -4,660.6% | -7,319.1% | -1,989.9% | 3,521.9% |
| Other Income/Exp. Net | -$14,836 | $37,697 | $4,179 | $16,765 |
| Pre-Tax Income | -$35,902 | $15,886 | -$17,710 | -$9,966 |
| Tax Expense | $0 | $0 | $0 | $287 |
| Net Income | -$35,902 | $15,886 | -$17,710 | -$10,253 |
| % Margin | -7,942.9% | 5,330.9% | -1,610% | 1,350.9% |
| EPS | -1.38 | 0.61 | -0.68 | -0.069 |
| % Growth | -326.2% | 189.7% | -885.5% | – |
| EPS Diluted | -1.38 | 0.6 | -0.68 | -0.069 |
| Weighted Avg Shares Out | 26,003 | 25,980 | 25,903 | 25,907 |
| Weighted Avg Shares Out Dil | 26,003 | 26,447 | 25,903 | 25,907 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1,548 | $1,748 | $2,015 | $7,386 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $606 | $589 | $1,156 | $486 |
| EBITDA | -$35,296 | $16,475 | -$20,733 | -$9,480 |
| % Margin | -7,808.8% | 5,528.5% | -1,884.8% | 1,249% |